Home > Publications Database > Plasma p-tau181 and GFAP reflect 7T MR-derived changes in Alzheimer's disease: A longitudinal study of structural and functional MRI and MRS. > print

001     274036
005     20250119000238.0
024 7 _ |a 10.1002/alz.14318
|2 doi
024 7 _ |a pmid:39558898
|2 pmid
024 7 _ |a pmc:PMC11667506
|2 pmc
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
024 7 _ |a altmetric:170887895
|2 altmetric
037 _ _ |a DZNE-2025-00017
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Göschel, Laura
|0 0000-0001-6592-2493
|b 0
245 _ _ |a Plasma p-tau181 and GFAP reflect 7T MR-derived changes in Alzheimer's disease: A longitudinal study of structural and functional MRI and MRS.
260 _ _ |a Hoboken, NJ
|c 2024
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1736338020_28059
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Associations between longitudinal changes of plasma biomarkers and cerebral magnetic resonance (MR)-derived measurements in Alzheimer's disease (AD) remain unclear.In a study population (n = 127) of healthy older adults and patients within the AD continuum, we examined associations between longitudinal plasma amyloid beta 42/40 ratio, tau phosphorylated at threonine 181 (p-tau181), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and 7T structural and functional MR imaging and spectroscopy using linear mixed models.Increases in both p-tau181 and GFAP showed the strongest associations to 7T MR-derived measurements, particularly with decreasing parietal cortical thickness, decreasing connectivity of the salience network, and increasing neuroinflammation as determined by MR spectroscopy (MRS) myo-inositol.Both plasma p-tau181 and GFAP appear to reflect disease progression, as indicated by 7T MR-derived brain changes which are not limited to areas known to be affected by tau pathology and neuroinflammation measured by MRS myo-inositol, respectively.This study leverages high-resolution 7T magnetic resonance (MR) imaging and MR spectroscopy (MRS) for Alzheimer's disease (AD) plasma biomarker insights. Tau phosphorylated at threonine 181 (p-tau181) and glial fibrillary acidic protein (GFAP) showed the largest changes over time, particularly in the AD group. p-tau181 and GFAP are robust in reflecting 7T MR-based changes in AD. The strongest associations were for frontal/parietal MR changes and MRS neuroinflammation.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a 7 Tesla
|2 Other
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a NeuroMET Memory Metric
|2 Other
650 _ 7 |a amyloid beta 42/40
|2 Other
650 _ 7 |a blood‐based biomarkers
|2 Other
650 _ 7 |a functional magnetic resonance imaging
|2 Other
650 _ 7 |a glial fibrillary acidic protein
|2 Other
650 _ 7 |a magnetic resonance imaging
|2 Other
650 _ 7 |a magnetic resonance spectroscopy
|2 Other
650 _ 7 |a memory
|2 Other
650 _ 7 |a mild cognitive impairment
|2 Other
650 _ 7 |a neurofilament light chain
|2 Other
650 _ 7 |a plasma biomarkers
|2 Other
650 _ 7 |a subjective cognitive decline
|2 Other
650 _ 7 |a tau phosphorylated at threonine 181
|2 Other
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Glial Fibrillary Acidic Protein
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a GFAP protein, human
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: blood
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a tau Proteins: blood
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Glial Fibrillary Acidic Protein: blood
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Magnetic Resonance Spectroscopy
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: blood
|2 MeSH
650 _ 2 |a Phosphorylation
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neurofilament Proteins: blood
|2 MeSH
700 1 _ |a Dell Orco, Andrea
|0 P:(DE-2719)9001684
|b 1
|u dzne
700 1 _ |a Fillmer, Ariane
|0 0000-0003-3333-6603
|b 2
700 1 _ |a Aydin, Semiha
|b 3
700 1 _ |a Ittermann, Bernd
|0 0000-0002-4087-471X
|b 4
700 1 _ |a Riemann, Layla
|0 0000-0001-5411-7288
|b 5
700 1 _ |a Lehmann, Sylvain
|0 0000-0001-6117-562X
|b 6
700 1 _ |a Cano, Stefan
|0 0000-0001-9390-273X
|b 7
700 1 _ |a Melin, Jeanette
|0 0000-0002-3700-3921
|b 8
700 1 _ |a Pendrill, Leslie
|0 0000-0003-4349-500X
|b 9
700 1 _ |a Hoede, Patty L
|0 0000-0003-3733-2845
|b 10
700 1 _ |a Teunissen, Charlotte E
|0 0000-0002-4061-0837
|b 11
700 1 _ |a Schwarz, Claudia
|0 0000-0003-3234-912X
|b 12
700 1 _ |a Grittner, Ulrike
|0 0000-0003-2595-0224
|b 13
700 1 _ |a Körtvelyessy, Peter
|0 P:(DE-2719)2812030
|b 14
|u dzne
700 1 _ |a Flöel, Agnes
|0 P:(DE-2719)2812683
|b 15
|e Last author
773 _ _ |a 10.1002/alz.14318
|g Vol. 20, no. 12, p. 8684 - 8699
|0 PERI:(DE-600)2201940-6
|n 12
|p 8684 - 8699
|t Alzheimer's and dementia
|v 20
|y 2024
|x 1552-5260
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/274036/files/DZNE-2025-00017.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/274036/files/DZNE-2025-00017.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:274036
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 1
|6 P:(DE-2719)9001684
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2812030
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2812683
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-25
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2023-10-25
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-10-25
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-25
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-25
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-25
920 1 _ |0 I:(DE-2719)5000081
|k AG Flöel
|l Dementia Prevention – Mechanisms and Clinical Implementation
|x 0
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000081
980 _ _ |a I:(DE-2719)5000006
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21